NSCEB Applauds ITC Investigation into Unfair Chinese Economic Practices to Distort the Biotechnology Market 

NSCEB Applauds ITC Investigation into Unfair Chinese Economic Practices to Distort the Biotechnology Market 

NSCEB Commissioners worked with Congress to include the investigation mandate in the recently passed FY26 CJS appropriations report.  

27 FEBRUARY 2026

FOR IMMEDIATE RELEASE

Washington, DC –

Yesterday the U.S. International Trade Commission took action on a recommendation from the NSCEB’s April 2025 report when it announced initiation of a new investigation into practices by the Chinese government that unfairly support Chinese biotechnology firms and undermine the competitiveness of American firms.  

The NSCEB made this recommendation in its April 2025 report, and Chairman Young along with congressional commissioners worked for its inclusion in the Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act for FY2026.  

Joint statement from NSCEB Chairman Senator Todd Young and Vice Chair Michelle Rozo: 

“Nearly a year ago, the NSCEB highlighted the risk posed by China’s brute force economic tactics and called for an ITC investigation into the anticompetitive practices that distort global biotechnology markets. We applaud the ITC for moving swiftly to open a new investigation into Chinese state support and pricing practices in the biotechnology sector.  

“If the ITC determines the Chinese government has manipulated markets and disadvantaged American biotechnology firms, that will enable subsequent executive branch action to level the playing field. We firmly believe that when American companies can compete on fair footing, we will win.” 

 

About NSCEB: The National Security Commission on Emerging Biotechnology is a time-limited, high-impact legislative branch advisory entity whose purpose is to advance and secure biotechnology, biomanufacturing, and associated technologies for U.S. national security and to prepare the United States for the bioindustrial revolution. The Commission published a comprehensive report in April 2025, including recommendations for action by Congress and the federal government. The bipartisan Commission is composed of Congressionally-appointed Commissioners with members from both the Senate and the House of Representatives as well as experts from industry, academia, and government. For more information about the Commission and to view the report, visit: biotech.senate.gov.

Contacts:

NSCEB: press@biotech.senate.gov